GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE278nnn/GSE278862/primaryOK200TranscriptomicsMus musculusExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE278862GEOGSEfalseDefective Autophagy in GNE Myopathy is Reversed by Inhibition of Supplementary mTOR Activation [cells RNA-seq]GNE myopathy, a recessive autosomal disease caused by mutations in Glucosamine-(UDP-N-Acetyl)-2-Epimerase/N-Acetylmannosamine Kinase (GNE), is characterized by deficient sialic acid (SA) production and the formation of rimmed vacuoles. Similar to other autophagic vacuolar myopathies, defective autophagy has been identified as a causative factor in GNE myopathy. However, the molecular mechanism underlying this defective autophagy has not been fully determined. Through transcriptome analysis of two GNE myoblast models derived from human pluripotent stem cells (hPSCs), several gene sets associated with autophagy were identified as pathogenic gene signatures of GNE myopathy. This prediction, along with subsequent biochemical validation using GNE knockout in C2C12 myoblasts (KO cells), revealed that high production of extracellular matrix promoted focal adhesion and subsequent activation of the AKT-mTORC axis, leading to inhibitory phosphorylation of ULK1 and impeding autophagy initiation in KO cells. Notably, transcriptome-based drug screening for candidates that inversely correlate with the pathogenic gene signature identified copanlisib, an FDA-approved PI3K inhibitor, as a potential therapeutic candidate for GNE myopathy. As predicted, copanlisib enhanced autophagy by inhibiting mTOR-dependent ULK1 phosphorylation. These results suggest that copanlisib could be a feasible therapeutic option for patients with GNE myopathy.2026/05/15GSE278862GSM8556174GSM855617517021278862Mus musculus[41963465]